# Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database

> **NCT06148493** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 425 (actual)

## Conditions studied

- Chronic Myeloid Leukemia

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06148493
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2022-09-20
- **Primary completion:** 2022-12-15
- **Final completion:** 2022-12-15
- **Target enrollment:** 425 (ACTUAL)
- **Last updated:** 2023-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06148493

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06148493, "Real-World Usage of Asciminib Among Patients With Chronic Myeloid Leukemia in Chronic Phase in the United States Using a Large Claims Database". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06148493. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*